FDA Approved Medication to Reduce Binge Eating and/or Purging

Status Completed

Clinical Trial Summary

This study will demonstrate the efficacy of Qsymia versus placebo in treating bulimia nervosa and binge eating disorder.

Clinical Trial Description

Bulimia nervosa (BN) and binge eating disorder (BED) are serious mental disorders associated with adverse psychological and physical consequences. Treatment options to date offer limited success, leaving at least 50-70% of patients still symptomatic after treatment. The purpose of the study is to evaluate whether phentermine-topiramate (Qsymia), a medication currently FDA approved for the treatment of obesity, will demonstrate efficacy—compared to placebo- when re-purposed for patients with bulimia and binge eating.

Participants will be randomized into one of two conditions: qsymia or Placebo. One condition will receive 3 months of phentermine-topiramate, a 2 week washout, then 3 months of placebo. The other condition will receive 3 months of Placebo, a 2 week washout, then 3 months of phentermine-topiramate. Participants will receive a total of 6 months of treatment and then have a 2 month follow-up off of medications. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02553824
Study type	Interventional
Source	Stanford University
Contact
Status	Completed
Phase	Phase 1
Start date	October 30, 2015
Completion date	April 15, 2017

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT04174703` - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing	N/A
Terminated	`NCT04278755` - Binge Eating & Birth Control	Phase 2
Withdrawn	`NCT02978742` - Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder	N/A
Withdrawn	`NCT00988481` - Topiramate Augmentation in Bulimia Nervosa Partial Responders	Phase 4
Completed	`NCT00184301` - A Comparison Study of Treatments Given to Patients With Concurrent Eating Disorder and Personality Disorder.	N/A
Completed	`NCT00522769` - Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents	Phase 1/Phase 2
Completed	`NCT00304187` - Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa	Phase 2
Recruiting	`NCT04409457` - Self-Control in Bulimia Nervosa	N/A
Recruiting	`NCT05509257` - Naltrexone Neuroimaging in Teens With Eating Disorders	Early Phase 1
Recruiting	`NCT05937243` - Identifying Effective Technological-based Augmentations to Enhance Outcomes From Self-help Cognitive Behavior Therapy for Binge Eating	N/A
Recruiting	`NCT05862389` - Study on the Mechanism of Eating Disorder
Recruiting	`NCT05728021` - Smartphone-based Aftercare for Inpatients With Bulimia Nervosa	N/A
Completed	`NCT03781921` - The Neural Bases of Emotion Regulation in Bulimia Nervosa
Recruiting	`NCT05575960` - Interpersonal Psychotherapy for Adolescents and Young Adults	N/A
Terminated	`NCT04041024` - Decision-making and Risk-taking in Bulimia	N/A
Completed	`NCT04265131` - Emotion Regulation in Eating Disorders: How Can Art Therapy Contribute to Treatment Outcome?	N/A
Recruiting	`NCT02960152` - Periodontal Impact of Eating Disorders (the PERIOED Study)	N/A
Completed	`NCT00916071` - Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders	N/A
Terminated	`NCT00308776` - Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa	N/A
Completed	`NCT03712748` - Online Imaginal Exposure	N/A